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Signal transduction pathway 
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Alireza tabibzadeh1, fahimeh Safarnezhad tameshkel2,3, Yousef Moradi4, Saber Soltani5, 
Maziar Moradi‑Lakeh3,6, G. Hossein Ashrafi7, nima Motamed8, farhad Zamani3, 
Seyed Abbas Motevalian9, Mahshid panahi3, Maryam esghaei1, Hossein Ajdarkosh3, 
Alireza Mousavi‑Jarrahi10 & Mohammad Hadi Karbalaie niya3*
the present study was conducted to evaluate the prevalence of the signaling pathways mutation rate 
in the Gastrointestinal (Gi) tract cancers in a systematic review and meta‑analysis study. the study 
was performed based on the PRISMA criteria. Random models by confidence interval (CI: 95%) were 
used to calculate the pooled estimate of prevalence via Metaprop command. the pooled prevalence 
indices of signal transduction pathway mutations in gastric cancer, liver cancer, colorectal cancer, and 
pancreatic cancer were 5% (95% CI: 3–8%), 12% (95% CI: 8–18%), 17% (95% CI: 14–20%), and 20% 
(95% CI: 5–41%), respectively. Also, the mutation rates for Wnt pathway and MAPK pathway were 
calculated to be 23% (95% CI, 14–33%) and 20% (95% CI, 17–24%), respectively. Moreover, the most 
popular genes were APC (in Wnt pathway), KRAS (in MAPK pathway) and PIK3CA (in PI3K pathway) 
in the colorectal cancer, pancreatic cancer, and gastric cancer while they were beta‑catenin and 
CTNNB1 in liver cancer. The most altered pathway was Wnt pathway followed by the MAPK pathway. 
in addition, pancreatic cancer was found to be higher under the pressure of mutation compared with 
others based on pooled prevalence analysis. finally, Apc mutations in colorectal cancer, KRAS in 
gastric cancer, and pancreatic cancer were mostly associated gene alterations.
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CCND1  Cyclin D1
CDHR1  Cadherin related family member 1
CTNNB1  Catenin beta 1
CGH  Comparative genomic hybridization
CISH  Chromogenic in situ hybridization
CAPRIN2  Caprin family member 2
DPC4  Deleted in pancreatic cancer-4
DHPLC  Denaturing high pressure liquid chromatography
ESCC  Esophageal squamous cell carcinoma
EGFR  Epidermal growth factor receptor
FLT3  FMS-like tyrosine kinase 3
FBXW7  F-box and WD repeat domain containing 7
FLG  Human filaggrin gene
GC  Gastric cancer
GI  Gastrointestinal
GBC  Gallbladder carcinoma
GNAS  Guanine nucleotide binding protein, alpha stimulating
CGH  Comparative genomic hybridization
GLTSCR1  Glioma tumor suppressor candidate region gene 1
HBV  Hepatitis B virus
HCV  Hepatitis C virus
HCC  Hepatocellular carcinoma
HPLC  High-performance liquid chromatography
HRM  High resolution melt
IHC  Immunohistochemistry
ISH  In situ hybridization
IPMN/IPMNC  Intraductal papillary mucinous neoplasm/carcinoma
ICC  Intrahepatic cholangiocarcinoma
IGF2R  Insulin like growth factor 2 receptor
JAK1  Janus kinase 1
KDR  Kinase insert domain receptor
KLHL22  Kelch like family member 22
LOH  Loss of heterozygosit
LM  Liver malignancy
mCRC  Metastatic colorectal cancer
MAPK  Mitogen-activated protein kinase
MSS  Microsatellite stable
MSI  Microsatellite instability
mTOR  Mechanistic target of rapamycin kinase
MSI-L  Microsatellite instability low
MSI-H  Microsatellite instability high
NGS  Next-generation sequencing
NOTCH1  Notch receptor 1
PC  Pancreatic cancer
PCR-SS  Polymerase chain reaction-sanger sequencing
PCR-SSCP  Single strand conformation polymorphism polymerase chain reaction
PCR-RFLP  Restriction fragment length polymorphism
PTEN  Phosphatase and tensin homolog
PTP  Protein tyrosine phosphatase
PTPN11  Protein tyrosine phosphatase non-receptor Type 11
PI3K  Phosphatidylinositol 3-kinase
PDGFRA  Platelet derived growth factor receptor alpha
PIK3CA  Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha
PMN  Papillary mucinous neoplasm
qRTPCR  Quantitative real-time polymerase chain reaction
RHOA  Ras homolog family member A
RNF169  Ring finger protein 169
RUNX1  Runt-related transcription factor 1
STK11  Serine/threonine kinase 11
SMO  Smoothened, frizzled class receptor
SOX9  SRY-box transcription factor 9
SMAD2  SMAD family member 2
SSCA  Single strand confirmation analysis
SSA/Ps  Sessile serrated adenoma/polyps
SNP  Single-nucleotide polymorphism
TGF-B  Transforming growth factor beta
TRPC4AP  Transient receptor potential cation channel subfamily C member 4 associated protein
VHL  Von Hippel–Lindau
VCAM1  Vascular cell adhesion molecule 1 
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WISP3  Wntl-inducible signaling pathway protein 3
WGS  Whole genome sequencing
WES  Whole-exome sequencing
Cell signaling is a communication process of cell activities mediated by downstream genes and proteins. Dis-
traction of signaling process induce disturbance in cellular mechanisms and may cause diseases, such as cancer, 
autoimmunity, and diabetes. In the major category, the signaling pathways are divided into intracellular activat-
ing signaling pathways, such as Hippo signaling and Notch signaling pathways or the extracellular activating 
pathways, for instance, Mitogen-activated protein kinase (MAPK) signaling, Nuclear factor κB (NF-κB), Janus 
 kinase1/signal transducer and activator of transcription (STAT) signaling pathway, Wnt signaling pathways, 
Hedgehog, Smad signaling pathway, and PtdIns 3-kinase (PI3) signaling pathways. The Smad signaling is criti-
cal in TGF-β signaling, which controls the transcription. MAPK signaling pathway makes use of three different 
downstream effectors, including Extracellular-signal-regulated kinase pathway, c-Jun N-terminal kinase (JNK) 
pathway, and p38 pathway. Also, the Wnt signaling pathway is important in cell differentiation and proliferation. 
In Wnt signaling, the Wnt/β-catenin signaling pathway is the only canonical  pathway2. The p53 signaling is not a 
canonical signaling pathway but due to the p53 non-transcriptional functions, the role of this pathway in generat-
ing cancer and its interaction with other signaling pathways, p53 can be considered as an individual  pathway3.
Gastrointestinal (GI) cancers are a group of cancers that affect the digestive system and its accessory organs. 
The most prevalent cancers related to GI tract are colorectal, gastric, and esophageal cancers,  respectively4. Muta-
tions in signaling pathways, such as signal transduction systems, are the basic triggering mechanisms in different 
types of  cancers5. The role of MAPK signaling pathway, Wnt, TGF beta, and JAK-STAT signaling pathways are 
more common in cancer induction. The Wnt signaling pathway, which include genes like PTEN (phosphatase 
and tensin homolog deleted on chromosome 10), WISP3 (Wnt1-inducible signaling protein 3), APC (Adeno-
matous polyposis coli), β-catenin, AXIN, and TCF4 (T-cell factor 4), has significant role in carcinogenesis. Thus, 
its microsatellite instability (MSI), among other carcinogenesis processes, has been a hot topic, especially in the 
studies of colorectal  cancer6–8. APC mutation and promoter hypermethylation are two important mechanisms 
in carcinogenesis and colorectal cancer (CRC)  progression9–11. Two AXIN genes, AXIN1 and AXIN2, could be 
prone to mutation in some CRC  cases12,13. PIK3CA (phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic 
subunit alpha) and PTEN are two important genes in the PI3K/AKT signal pathway and previous studies have 
put emphasis on them as important genes in the CRC development by altering the proliferation and cell death 
 patterns14,15. Moreover, CTNNB1 (catenin beta 1) transformation via β-catenin alteration as another mediators of 
the Wnt/β-catenin pathway have been found in some of the liver  tumors16. Liver carcinogenesis process is related 
to the interactions of three major pathways: the p53/p21, the p16/cyclin D1/pRB, and the Wnt/wingless17,18. Also, 
numerous factors such as TNFα (tumour necrosis factor alpha), TGFβ (transforming growth factor beta), c-myc, 
IGF2R (insulin like growth factor 2 receptor), SMAD2, SMAD4, DLC-1, and HIC1 (HIC ZBTB transcriptional 
repressor 1) could initiate liver  tumorogenesis17,18.
Mutation analysis of signaling pathway mediators could have prognostic impact on tumor development. 
Transformation of the epidermal growth factor receptor (EGFR) and its downstream pathway mediators could 
lead to development of human  tumors19. Two vital intracellular pathways affected by EGFR are the RAS/RAF/
MAPK and the PIK3CA/PTEN/AKT signaling pathways. These pathways mediate activation of transcription 
factors like ERK (extracellular regulated MAP kinase) and p38 and lead to cell transformation reactions like 
the up-regulation of proliferation, relocation, mesenchymal separation induction, and apoptosis reduction. As 
EGFR has been a target for anti-tumor drugs, its mutations and related downstream signaling pathway muta-
tions have become  important20.
Indeed, interaction of various signaling pathway mediator mutations and their behavior in cancer develop-
ment has been a hot topic. These alterations could include susceptibility, resistant or non-sense for treatment 
management or tumorogenesis in different individuals geographically. By considering the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses)  criteria21, we made an attempt to evaluate the 
prevalence of the signaling pathways mutation rate in the GI tract cancers in a systematic review and meta-
analysis setting.
Results
Search results. A total of 10,808 records were detected using the search strategy keywords. After screening 
by the title and abstracts, 414 articles were included for further analysis. Next, the full-text assessment resulted 
in selecting 121 eligible records including 65 studies on colorectal cancer (CRC), 21 on liver cancer (LC), 16 on 
Gastric Cancer (GC), 9 on pancreatic  cancer1, and 15 on other gastrointestinal cancers, namely esophagus, bile 
duct, rectal cancer, gall bladder, and ampullary adenocarcinomas. The details of screened data based on PRISMA 
guideline are provided in Fig. 1. The numbers of participants for the assessment of the GI cancer mutations 
induced 17,269, 1056, 2500, 378, 1080 individuals for CRC, LC, GC, PC, and other GI cancers, respectively.
Bias assessment. The risk of bias assessment is given in Table 1. Also, the RTI tool for the risk of bias deter-
mined one study with high risk of Selection Bias. Also, the Selection Bias, Performance Bias, Detection Bias, and 
Selective Outcome bias indicated 25, 3, 4, and 33 studies with unclear risk of bias, respectively. Furthermore, 
high risks of Selection Bias and Selective Outcome Bias were evaluated in 3 and 2 references, respectively.
Signaling pathways mutations in gastric cancer. From among 16 studies on GC, mostly the MAPK 
and PI3 pathways were analyzed in 2489 participants. The most evaluated gene in MAPK was KRAS and muta-
4
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:18713  | https://doi.org/10.1038/s41598-020-73770-1
www.nature.com/scientificreports/
tions ranged from 0 to 20%. Also, the PI3K mutations in the PI3 pathway were 3 to 8.7% and CTNNB1 mutations 
ranged from 1.7% to 7%. The detailed data are listed in Table 2 and supplementary Table 2.
The results of meta-analysis revealed that pooled prevalence index of signal transduction pathway mutations 
in GC was 5% (95% CI: 3–8%) and there was high heterogeneity between these studies in estimating the preva-
lence (I-squared = 91.25%, P = 0.001) (Fig. 2). Also, since the CI of the test (Egger’s test) does not include zero, 
there is no bias in our results (Egger’s test = 3.51, P = 0.0001, 95% CI: 2.49 to 4.53). The pooled prevalence funnel 
plot in GC signal transduction pathway mutations is illustrated in Fig. 2. Furthermore, the Subgroup analyses 
of pooled prevalence Signal Transduction Pathway Mutations in GC are summarized in Table 3.
Signaling pathways mutations in cRc . CRC related signaling pathway mutation was found in 65 stud-
ies. A majority of study samples had the mean age > 60 years and male/female ratios of CRC incidence in most 
of the evaluated studies were reported more than 2:1. The most prevalent mutation analysis was taken from 
KRAS exon 2, BRAF exon 15, PIK3CA exon 9 and 20, and APC and beta-Catenin exon 3. Most of the studies 
were cross-sectional and total CRC patients included 17,269 cases. These studies reported different mutation 
rates based on the sample size, selected gene, and method of use. The results showed a wide range of mutation 
in different pathways and related genes as listed in supplementary Table 3. The KRAS mutations in the MAPK 
pathway were 2.5 to 75% and the BRAF (B-Raf proto-oncogene, serine/threonine kinase) mutations ranged from 
0 to 78.6%. The Wnt signaling mediator mutations, such as beta-catenin, were reported from 3 to 37.5% and 
APC mutations ranged from 28.4 to 73%. The p53 was assessed in 5 studies and its mutation rate was reported 
18–65% (Table 2).
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Figure 1.  PRISMA Flow Diagram of our study population, the diagram indicates the primary search item 
frequencies, duplicates, Studies included in qualitative synthesis and Studies included in quantitative synthesis.
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Author Year Country Selection bias Performance bias Detection bias Attrition bias Selective outcome Confounding Ref
1 Müller 1998 Germany ? ? + * + + 22
2 Sparks 1998 USA − ? + * + + 23
3 Kondo 1999 Japan − + + * + + 16
4 Koyama 1999 Japan ? + + * ? + 24
5 Shitara 1999 Japan + + + * ? + 25
6 Mirabelli 1999 Canada + + + * + + 26
7 Huang 1999 France + + + * + + 27
8 Wong 2001 China + + + * + + 28
9 Fujimori 2001 Japan + + + * + + 29
10 Kawate 2001 Japan ? + + * ? + 30
11 Rashid 2001 China + + + * + + 31
12 Shitoh 2001 Japan + + + * + + 32
13 Chen 2002 Taiwan ? + + * ? + 33
14 Taniguchi 2002 United States + + + * + + 34
15 Clements 2002 USA + + + * ? + 35
16 Engeland 2002 Netherlands + + + * + + 36
17 Yuen 2002 UK ? + + * + + 37
18 Abraham 2002 United States ? + + * + + 38
19 Yoo 2002 South Korea + + + *  + + 39
20 Tannapfel 2003 Germany ? + + * + + 40
21 Jass 2003 Australia + + + * + + 41
22 Zhang 2003 Japan + + + * + + 42
23 Sakamoto 2004 Japan + + + * ? + 43
24 Bläker 2004 Germany ? + + * ? + 44
25 Fransén 2004 Sweden + + + * + + 45
26 Li 2005 China + + + * + + 46
27 Immervoll 2005 Norway + + + * − + 47
28 Pasche, 2005 USA + + + * + + 48
29 Thorstensen 2005 Norway + + + * + + 49
30 Noda 2006 Japan + + ? * ? + 50
31 Mikami 2006 Japan + + + * + + 51
32 Schönleben 2008 USA + + + * ? + 52
33 Ching-Shian Leong, 2008 Malaysia + ? ? * ? + 53
34 Nomoto 2008 Japan ? + + * + + 54
35 Schonleben 2008 Germany ? + + * + + 55
36 Pan 2008 China + + + * + + 56
37 Kim 2008 Korea + + + * + + 57
38 Xie 2009 Korea + + + * + + 58
39 Seth 2009 UK − + + * + + 59
40 Cieply 2009 USA + + + * + + 60
41 Dahse 2009 Germany + + + * + + 61
42 Kim 2009 South Korea + + + * + + 62
43 Packham 2009 Australia + + + * ? + 63
44 Baldus 2010 Germany + + + * + + 64
45 Irahara 2010 USA + + + * + + 65
46 Smith 2010 UK +  + + * ? + 66
47 Liao 2010 China ? + + * ? + 67
48 Catenacci 2011 USA + + + * + + 68
49 Watanabe 2011 Japan + + + * + + 69
50 Metzger 2011 Luxembourg + + + * ? + 70
51 Naghibalhossaini 2011 Iran + + + * −  + 71
52 Sameer 2011 India + + + * + + 72
53 Purcell 2011 New Zealand + + + ? + + 73
54 Ueda 2011 Japan + +  + * + + 74
55 Mohri 2012 Japan ? + + * + + 75
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Author Year Country Selection bias Performance bias Detection bias Attrition bias Selective outcome Confounding Ref
57 Bond 2012 Australia + + + ? + + 77
58 Laghi 2012 Italy + + + * + + 78
59 Levidou 2012 Greece + + + * + + 79
60 Lee 2012 Korea + + + * + + 80
61 Li 2012 China + + + * ? + 81
62 Paliga 2012 Canada + + + * ? + 82
63 Voorham 2012 Netherlands + + + * + + 83
64 Whitehall 2012 Australia + + + * + + 84
65 Khiari 2012 Tunisia + + + * ? + 85
66 Tai 2012 Taiwan + + + * + + 86
67 Ree 2012 Norway + + + * + + 87
68 Chen 2013 Taiwan + + + * ? + 88
69 Garcia-Carracedo 2013 USA ? + + * + + 89
70 Hidaka 2013 Japan + + + * ? + 90
71 Kan 2013 USA + + + * + + 91
72 Saigusa 2013 Japan + + + * +  + 92
73 Shi 2013 China ? + + * ? + 93
74 Aissi 2013 Tunisia + + + * ? + 94
75 Fleming 2013 USA + + + * + + 95
76 Long 2013 China + + + * + + 96
77 Van Grieken 2013 UK, Japan, Singa-pore + + + * ? +
97
78 Gurzu 2013 Romania + + + * + + 98
79 Wang 2013 USA + + + * + + 99
80 Han 2013 Korea + + + * ? + 100
81 Neumann 2013 Germany + + + * + + 101
82 Shen 2013 China + + + * + + 102
83 Yip 2013 Malaysia ? + + * + + 103
84 Zhang 2014 China + + + * + + 104
85 Mohammadi asl 2014 Iran + + + * ? + 105
86 Chen 2014 China + + + * + + 106
87 Lee 2014 Korea + + + * ? + 107
88 Ahn 2014 Korea + + + * ? + 108
89 Chang 2014 Taiwan ? + + * + + 109
90 Jia 2014 China ? + ? * ? + 110
91 Wang 2014 USA, China + + + * + + 111
92 Zhu 2014 China + + + * + + 112
93 Tong 2014 PR China + + + * + + 113
94 Gao 2014 China + + + * ? + 114
95 Li 2014 China ? + + * + + 115
96 Saito 2014 Japan ? + + * + + 116
97 Schlitter 2014 Germany ? + + ? + + 117
98 Marchio 2014 Peru + + + * + + 118
99 Mikhitarian 2014 USA ? + + * + + 119
100 Yoda 2015 Japan ? + + * + + 120
101 Zaitsu 2015 Japan + + + * + + 121
102 Lu 2015 China ? + + * ? + 122
103 Kawamata 2015 Japan + + + * ? + 123
104 Lan 2015 Taiwan + + + * + + 124
105 Samara 2015 Greek + + + * + + 125
106 Abdelmaksoud Damak 2015 Tunisia + + + * ? +
126
107 Kawazoe 2015 Japan + + + * + + 127
108 Lin 2015 USA + + + * + + 128
109 Suarez 2015 France + + + * ? + 129
110 Witkiewicz 2015 USA + + + * + + 130
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The results of meta-analysis revealed that pooled prevalence of signal transduction pathway mutations in 
CRC was 17% (95% CI: 14%, 20%) and there was a high heterogeneity between these studies in estimating the 
prevalence (I-squared = 97.63%, P = 0.0001) (Fig. 3). Also, the subgroup analysis for heterogeneity was performed 
in CRC included studies based on the different pathways (heterogeneity plot in Fig. 4), detection method (het-
erogeneity plot in Fig. 5), and involved genes (heterogeneity plot in Fig. 6). The CI of test (Egger’s test) included 
zero, thus there was no significant bias in the results (Egger’s test = − 0.692, P = 0.109, 95% CI: − 1.54 to 0.156). The 
pooled prevalence funnel plot in CRC signal transduction pathway mutations is illustrated in Fig. 7 and the Sub-
group analyses of pooled prevalence signal transduction pathway mutations in CRC are summarized in Table 3.
Signaling pathway mutations in liver cancer (Lc). The search on liver cancer resulted in a total of 
1056 hepatocellular carcinoma (HCC) and 174 hepatoblastoma participants in 21 studies. There were different 
ranges of mutations in these studies, which are listed in supplementary Table 4. The Wnt signaling was the most 
evaluated pathway in which the CTNNB1 gene mutation ranges were evaluated to be 12–75% and the beta-
catenin genes had the mutation ranges of 2.8–41%. In addition, the mutation ranges in p53 were 1.2 to 61% and 
the JAKs in the JAK signaling pathway were observed to be 1.2 to 16%.
The results of meta-analysis showed that pooled prevalence of signal transduction pathway mutations in LC 
was 12% (95% CI: 8–18%) and there was a high heterogeneity between these studies in estimating the prevalence 
(I-squared = 85.34%, P = 0.0001) (Fig. 8). Also, since the CI of the test (Egger’s test) included zero, there was no 
significant bias in the results (Egger’s test = − 0.442, P = 0.411, 95% CI: − 0.65 to 1.53). The pooled prevalence fun-
nel plot in LC signal transduction pathway mutations is illustrated in Fig. 8. Furthermore, the Subgroup analyses 
of pooled prevalence signal transduction pathway mutations in LC are summarized in Table 3.
Signaling pathways mutations in pancreatic  cancer1. In a total of 9 studies, 392 PC patients were 
studied with the KRAS and PIK3CA mutations reported 42 to 92% and 2.7 to 12%, respectively. More data are 
shown in supplementary Table 5.
The results of meta-analysis showed that pooled prevalence of signal transduction pathway mutations in 
pancreatic cancer was 20% (95% CI: 5–41%) and there was a high heterogeneity between these studies in esti-
mating the prevalence (I-squared = 97.14%, P = 0.0001) (Fig. 9). Also, the CI of the test (Egger’s test) included 
zero, s no significant bias was present in the results (Egger’s test = − 1.351, P = 0.568, 95% CI: − 6.37 to 3.66). The 
pooled prevalence funnel plot in PC signal transduction pathway mutations is illustrated in Fig. 9. Furthermore, 
the Subgroup analyses of pooled prevalence signal transduction pathway mutations in pancreatic cancer are 
summarized in Table 3.
Signaling pathways mutations in other Gi cancers. The other GI cancers included gastro-esophageal 
cancer, rectal cancer, esophageal squamous cell carcinoma, gallbladder carcinoma, and cholangiocarcinoma. 
Different signaling pathways in these GI cancers are listed in supplementary Table 6. Briefly, KRAS was the 
popular gene for mutation analysis ranging from 0% mutation in squamous cell anal carcinoma to 57% in small 
intestinal adenocarcinoma. BRAF was analyzed in 6 studies with its mutation reported to be 0–45%. Moreover, 
APC mutations were reported between 9.5 and 47% in different malignancies.
Signaling pathway mutation association with clinic‑pathological features and patients sur‑
vival. The extracted data about clinic-pathological features and patients survival were listed in supplement 
Tables 2 to 6. As glimpse, the clinic-pathological features statistically significant in association with signaling 
pathway mutations that they were mentioned in 2 individual studies for gastric cancer and 30, 6, 1 and 2 indi-
vidual studies for CRC, LC, PC and other GI cancers, respectively.
Survival rate assessment in association with signaling pathway mutations were listed in supplement Tables 2 
to 6. The survival rate or prognostic feature in association with signaling pathway mutations were mentioned in 
1, 6, 1, 1, 0 and 1 included studies for CRC, LC, PC and other GI cancers, respectively.
Author Year Country Selection bias Performance bias Detection bias Attrition bias Selective outcome Confounding Ref
112 Grellety 2016 France + + + * ? + 132
113 Jauhri 2016 India + + + * ? + 133
114 Nam 2016 Republic of Korea + + + * + + 134
115 Dallol 2016 Saudi Arabia + + + * + + 135
116 Yuan 2016 China ? + + * + + 136
117 Ziv 2017 New York ? + ? * + + 137
118 Ho 2017 Hong Kong + + + * + + 138
119 Hänninen 2018 Finland + + + * + + 139
120 Mizuno 2018 USA + + + * + + 140
121 Yang 2018 China + + + * + + 141
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Cancer type (number 
of studies)
Pathway (number of 
studies)






MAPK (n = 43)
KRAS (n = 46)
1 24 86 142
1, 2 14.6 48 43
2 34–44.9 1167 64,101,106,125,127,141
2, 3, 4 49 37 59
3, 4 3.8 264 127
NR 2.5–75 11,561 36,42,45,50,51,63,65–67,69,71,77,79,83,84,86,92,94,98,99,102,103,107–109,112,113,123,124,128,132,134,135
BRAF (n = 33)
NR 0–78 8146 37,45,50,51,63,65,67,71,77–79,83,84,93,98,108,109,112,127,128,132,134
11, 13–15 10 37 59
11, 15 6.9 676 102
15 2.3–46.2 982 64,79,101,103,105,106,125,141
Wnt (n = 18)
beta-catenin (n = 6)
3 3–37.5 491 26,29,32,51
NR 4–27 97 22,42
APC (n = 10)
NR 28–73 750 41,83,88,99,107,128,135
15 50–52 180 32,126
AXIN2 (n = 2) 7, 8 1.4–20 381 49,62
CTNNB1 (n = 7)
3 1.3–16 274 85,126
NR 1–48 387 23,83,128,133
PI3 (n = 15)
PIK3CA (n = 17)
9, 22 0–21 1556 51,53,64,67,101,102,106
NR 0–34 3634 65,83,84,107,109,112,124,127,128,134,135
PTEN (n = 7)
1–9 0 49 103
8 17 310 49
NR 0–28 459 83,128,133,135
P53 (n = 5) P53 (n = 5) NR 18–63 1589 49,77,99,128,135
LC
(n = 21)
MAPK (n = 3)
KRAS (n = 3)
2–18 0 25 40
NR 4–16 92 118,122
BRAF (n = 2) NR 0 105 40,118
Wnt (n = 15)
beta-catenin (n = 8)
NR 15–70 225 33,34,91,129
3 2.8–41 156 16,27,28,57
AXIN (n = 3)
3–5 25 36 57
NR 2–12.5 153 34,118
CTNNB1 (n = 7)
3 12–75 370 34,60,73,74,131
NR 15–31 86 110,118
P53 (n = 4) TP 53 (n = 4) NR 1.2–61 296 91,96,118,122
PC
(n = 9)
MAPK (n = 5)
KRAS (n = 6)
1 47–67 79 47,55
2 27 11 75
NR 42–92 199 52,119,130
BRAF (n = 4)
5, 11, 15 0–2.7 79 47,55
NR 0–2.7 90 52,119
Wnt (n = 2)
beta-catenin (n = 1) 3 23 21 38
AXIN (n = 1) NR 5 109 130
PI3 (n = 4) PIK3CA (n = 5)
All 11 36 55
NR 4–11 147 52,130
9 12 52 119
9, 20 2.7 36 89
GC
(n = 16)
MAPK (n = 5) KRAS (n = 4)
1 14 104 39
2 0 34 141
NR 4.2–20 767 97,120
Wnt (n = 6)
AXIN1 (n = 2) NR 3.8–7.1 200 56,90
AXIN2 (n = 3) NR 4.6–9.8 292 56,62,90
APC (n = 1) NR 2.5 237 80
CTNNB1 (n = 4)
NR 1.7–3.6 322 80,90,120
3 7.1 70 56
PI3 (n = 5)
PIK3CA (n = 5)
NR 5.1–7.2 292 80,120
1, 9, 20 4.3–8.7 325 46,76
18 3 100 104
PTEN (n = 1) NR 20 221 121
AKT (n = 1) 6 2 100 104
Table 2.  GI tract cancer signaling pathway mutations based on genes and exon (n = 121). NR not reported.
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Discussion
The aim of the current study was to evaluate the prevalence of the signaling pathway mutation rate in GI tract 
cancers in a systematic review and meta-analysis setting. It should note that, the signaling pathway mutations 
were comprehensively studied by The Cancer Genome Atlas (TCGA)1. Furthermore, the inclusion criteria for 
the current study were different with TCGA assessments. Also, this study could be a lead for further investiga-
tions in the field of the signaling pathway mutations prevalence and might be useful for further TCGA com-
prehensive updates. Appropriate keywords were used for search strategy in popular academic databases. Data 
were screened and eligibility of the studies was evaluated according to the inclusion criteria. PRISMA guideline 
Table 3.  Subgroup analysis of pooled prevalence of Signal Transduction Pathway Mutations in GC, CRC, 
HCC, and PC based on gene, pathway, and method of diagnosis. GC: gastric cancer; CRC: colorectal cancer; 
HCC: hepatocellular carcinoma; PC: pancreatic cancer. SS: Sanger Sequencing, SSCP: Single-stranded 
conformation polymorphism; HPLC: High-performance liquid chromatography, NGS: next-generation 
sequencer, ARMS-PCR: amplification refractory mutation system polymerase chain reaction.
Outcome Subgroup No. of studies Summery Odds Ratio (95% CI)
Between studies

























































































































































































Beta-Catenin 7 20% (10–31%) 77.20% 0.001 6.06
Pathway
Wnt 13 17% (11–23%) 72.34% 0.001 9.11















KRAS 5 58% (31–83%) 93.64% 0.001 5.60
PIK3C 4 6% (3–10%) 14.84% 0.320 5.13
Pathway
MAPK 8 31% (5–66%) 97.66% 0.001 4.75
PI3 4 6% (3–10%) 14.84% 0.320 5.13
Method for detection
PCR, SS 11 31% (5–66%) 92.05% 0.001 3.84
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Figure 3.  Heterogeneity plot of the included studies for CRC signal transduction pathway mutations.
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was used as the study protocol. Through the search strategy, we found that GI malignancies included CRC, LC, 
PC, GC, esophageal cancer, rectal cancer, and bile duct neoplasm or cholangiocarcinoma. The results obtained 
in the current study showed that most alterations in CRC patients were in the KRAS gene in MAPK pathway 
within the range of 3.8 to 54.5%. These differences could be due to the study population or the methodology in 
different studies although the cancer stage and other risk factors could also play major roles. Furthermore, the 
pooled prevalence indices of signal transduction pathway mutations in GC, CRC, LC, and PC were 5% (95% CI: 
3–8%), 17% (95% CI: 14–20%), 12% (95% CI: 8–18%), and 20% (95% CI: 5–41%), respectively. The higher rates 
in pooled prevalence could suggest more association between the signal transduction mutations and GI cancers 
incidence. The subgroup analysis for CRC shows that KRAS and APC are the most mutant genes with 32% (95% 
CI, 29–36%) and 44% (95% CI, 33–55%) mutation rates, respectively. Also, the most altered pathway was Wnt 
(23%) (95% CI, 14–33%), followed by MAPK (20%) (95% CI, 17–24%) pathway.
The CRC carcinogenesis is firstly initiated by the mild colon polyps and gradually progresses to the cancer-
ous lesions. The adenocarcinoma is globally the most prevalent type of the CRC 143,144. Recently, different studies 
have been reported focusing on the cost-effectiveness of the CRC screening programs indicating the importance 
of the CRC  diagnosis145,146. Signaling pathways have crucial impacts on the development of different  cancers5. 
Although the nucleotide alterations have critical impacts on cancer initiation, the environmental factors are pre-
disposing elements in cancer induction and are affecting the signaling pathways  mutations147,148. As an example, 
smoking affects CRC cancers generation and  mortality149–151. In this regard, lung cancer investigations revealed 
that smoking could increase the EGFR and its downstream elements, such as KRAS and BRAF  mutations148. 
Moreover, studies on CRC and smoking showed that TGFβ signaling pathway mutations have significant roles 
in  carcinogenesis147. Inflammation is another key player in generation of  cancer152,153. TLR2 alterations associ-
ated with inflammation could lead to the signaling pathways related ERK (extracellular-regulated kinase) and 
PI3K/AKT mutations. The importance of the inflammation in the CRC were illustrated by Liu and et al.154. These 
substitutions might be due to the microbiome disturbance,  too155.
The MAPK/ERK signaling was analyzed in the study reported by Sameer et al.156 who found KRAS mutation 
to be 24% in 86 CRC patients. Meanwhile, Tong et al.113 reported the highest rate (75%) of the KRAS mutations 
in CRC patients in codon 12 in 1506 individuals. Tong’s study showed different mutation rates between the 
separate codons of the KRAS gene with the highest in codon 12 and the lowest (2.5%) in codon 61. Also, in the 
study conducted by Kawazoe et al.127 on 264 metastatic colorectal cancers (mCRC), the KRAS exon 2 mutation 
was calculated to be 34%, as the highest mutation rate. In this study, BRAF mutation rate was reported to be 
5.4%. The highest prevalence for the BRAF mutation reported in other studies was 78%88. This huge difference 
in the BRAF mutation rate could be due to the differences in the sample size and the method used for analysis.
The Wnt/beta-catenin signaling and PI3K/AKT signal have been assessed in a variety of studies. The Wnt/
beta-catenin was assessed in 18 different studies and the most evaluated genes were APC, beta-catenin, and 
CTNNB1. Fujimori et al.26 showed that 37.5% of the 73 CRC patients had mutations in the exon 3 of the beta-
catenin gene. Also, Shitoh et al.32 reported the rate of 3% for beta-catenin mutation in exon 3, and 27% in the 
high-frequency microsatellite instability (MSI-H). Furthermore, the APC gene mutations were assessed in 10 
different studies with the lowest reported to be 33% in the study by  Chen88 study and the highest as 73% reported 
by Lee et al.107. The previous studies showed that the MSI could be associated with the in/del substitutions in 
genome hot spots which can initiate CRC tumorogenesis by increasing the mismatches  indiscriminately157–159. 
Investigation on Wnt/beta-catenin signaling was firstly introduced by the association between APC gene and 
beta-catenin160,161. Other studies found the interactions of these genes with beta-catenin-Tcf (T-cell factor) 
complex suggesting the association of these genes with CRC omplication 162. The role of APC gene in causing 
cancer was initially introduced in the familial adenomatous polyposis (FAP)163. This gene facilitates beta-catenin 
distorting. APC gene mutations influence beta-catenin and AXIN protein binding  sites164,165. Moreover, they 
could maximize the protein stability and life  cycle166. Thus, the carcinogenesis process is accelerated by altered 
signal transduction and cell  cycle167.
Figure 7.  Pooled prevalence funnel plot in CRC signal transduction pathway mutations.
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Figure 9.  Heterogeneity and pooled prevalence funnel plot of the included studies for pancreatic cancer (PC) 
signal transduction pathway mutations.
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From among the studies which assessed the PI3 signal transduction pathway, the mutation of PIK3CA gene 
was reported in 20 studies ranging between 0 and 34%. Meanwhile, Thorstensen et al.49 found p53 gene mutation 
rate to be about 18% in CRC patients.
There are variable reports in the matter of clinic-pathological association with mutations in the current 
study. In the conducted study by Sameer et al.156 the clinic-pathological assessment indicated that, the SMAD4 
mutations are more frequent in colon tumors and statistically associated with tumor grade and lymph nodes 
involvement. Tong and  colleagues113 reports the KRAS mutations are in association with gender and tumor site. 
Also, Kawazoe et al.127 points out the BRAF mutations are associated with tumor location, site of metastasis and 
differentiation pattern. Meanwhile, Yang and  colleagues168 reports the association of the KRAS mutations with 
tumor location, type of tumor, differentiation pattern and gender of the patients. Furthermore, there were limited 
data about the association of the mutations in signaling pathways with survival rate in patients. Some studies 
suggested BRAF  mutations169 and SMAD4  mutations140 are association with poor prognosis and survival rate. 
Highly variable and limited data about clinic-pathological features, survival and prognosis in association with 
signaling pathway mutations were extracted. The clinic-pathological features and patients survival association 
with signaling pathway mutations is one of the current study limitations and needs further investigation.
HCC is the fifth cause of death worldwide and is mostly inducted by the chronic liver disorders, such as viral 
 hepatitis170,171. In LC patients, the Wnt signaling was the top research interest and the CTNNB1 was the most 
assessed gene. The CTNNB1 mutation was also investigated in HCC patients in different  studies118,129,131. Purcell 
et al.73 reported CTNNB1 mutations in 15% of hepatoblastoma patients while the reported prevalence in Ueda’s 
study was 75%74. Our study subgroup analysis for liver  cancer145 studies showed that beta-catenin has higher 
mutation rate (20% (95% CI, 10–31%)) and the most altered pathway was Wnt (17% (95% CI, 11–23%)). It has 
been indicated that the CTNNB1 and P53 genes are the most involved genes in the  HCC172,173. Moreover, the 
conducted studies showed that the P53 mutations were mostly associated with the Asian and African countries, 
while the CTNNB1 mutations were mostly associated with HCC in the Western  countries172,173.
The pancreatic cancer is known as the forth cause of cancer mortality in the US with only 10% of the cases 
living more than 5 years174. Witkiewicz et al.130 assessed different genes in MAPK/ERK, PI3K/AKT, and Wnt/
beta-catenin signaling pathways in pancreatic ductal adenocarcinoma patients. They showed that the AXIN1, 
KRAS, and PI3CA mutations rate were 5%, 92%, and 4%, respectively. Moreover, the high rate of KRAS mutations 
in pancreatic cancer patients was confirmed by the other  studies55,119,175. Our study showed that in the subgroup 
analysis for pancreatic cancer, the KRAS was the most mutated gene (58% (95% CI: 31–83%)) and MAPK was 
the most altered pathway (31% (95% CI: 5–66%)). In GC, mutations were 14% (95% CI: 2–34%) for KRAS, 7% 
(95% CI: 1–17%) for MAPK, and 6% (95% CI: 2–12%) for PI3 pathways. In the pancreatic and gastric cancers, 
the most evaluated pathways were PI3 and MAPK. The KRAS gene generates a GTPase protein which is critical 
in regulating the cell proliferation and  metabolism176. The mutations in KRAS leads to impaired cells activity 
enhancement and malignancy  progression177.
Gastric Cancer (GC), as another invasive GI cancer, has significant mortality rate  worldwide178. Zhang et al.104 
studied 100 advanced primary GC cases for the purpose of evaluating PI3K/AKT signaling pathway muta-
tions. They suggested that the MAPK/ERK and PI3K/AKT pathways could be potential therapeutic targets 
for GC  treatment179,180. The AKT gene produced a protein in the PI3K/Akt pathway which could play a role in 
 tumorogenesis80. The mutations in the PIK3CA and AKT in PI3K/AKT pathway could affect downstream signal-
ing pathway genes, like mTOR (mechanistic target of rapamycin kinase) and caspase 9, which are important in 
GC  progression104,181,182. Wang et al.99 investigated hedgehog pathway in GC patients and showed that the PTCH1 
(patched 1) and SMO (smoothened) genes were mutated in 51.2% and 25.6% of the cases. Alterations in PTCH1 
gene were associated with the basal cell carcinoma and basal cell nevus  syndrome183,184.
Moreover, most of the studies included used PCR followed by the Sanger sequencing, as the method of 
choice. However, some studies used SSCP-PCR (single-strand conformational polymorphism PCR) to detect 
mutation. The method used the least was the NGS (next generation sequencing) as a preferred method in the 
recent years. The NGS can be used to analyze numerous samples at the same time and thus reduce the cost and 
the time  required185. But the Sanger sequencing is an accurate and sensitive method for mutation analysis and 
it has been suggested for the confirmation of the NGS  results186. Also, in the subgroup analysis for the GC, the 
method of detection could be mentioned as a potent source of the heterogeneity in the current study (Table 3).
The major limitation in the current study was the extent of subject; it is suggested that further investigations 
use more narrowing strategies. Also, we aimed at minimizing the author bias in data extraction and screening 
biases using different authors and double check strategies. Also, it should be mentioned that the p53 signaling 
is not a canonical signaling pathway but due to the p53 non-transcriptional functions, the importance of this 
pathway in cancer generation, and its interaction with other signaling pathways, in the present study, we assessed 
p53 as individual  pathway3.
In conclusion, progression of GI cancers is affected by signaling pathway mediators. Different studies have 
shown diverse results based on their population, method, and target gene. Our study concluded that the most 
important genes that are under mutation pressure include KRAS and PI3CA in the CRC, PC, and GC while 
beta-catenin and CTNNB1 are genes under mutation pressure for liver malignancies. Subgroup analysis and 
heterogeneity of the studies could illustrate more valid data between different studies for screening strategies. In 
this regard, signal transduction pathway mutations pooled prevalence was higher in PC and lower in GC (20% 
vs. 5%). Thus, PC is the most common cancer involved by signal transduction mediator’s mutations. Among 
studied genes, KRAS in GC and pancreatic cancer and APC in CRC had the most association with cancer out-
come. Moreover, MAPK had higher mutation rate among the studied pathways. Furthermore, PCR-SS method 
had the highest popularity among different methods. Future studies should be carried out to focus on cancer 
progression and patient’s survival assessments.
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Methods
Search strategy. In the present comprehensive study, we assessed all relevant original research studies via 
the electronic literature search in Web of Science (SCIE), PubMed (Including MEDLINE), Science Direct, Sco-
pus, EMBASE, and Google Scholar databases using the keywords including Polymorphism, Mutation, Mutation 
Rate, Mutation Prevalence, Silent Mutation, Point Mutation, Missense Mutation, INDEL Mutation, Frameshift 
Mutation, Synonymous Mutation, Non-synonymous Mutation, Transversion Mutation, Transition Mutation, 
Insertion Mutation, Deletion Mutation, Digestive System Diseases, Gastrointestinal Neoplasms, Digestive Sys-
tem Abnormalities, Biliary Tract Diseases, Biliary Tract Neoplasms, Gallbladder Diseases, Anorectal Malfor-
mations, Colorectal Neoplasms, Pancreatic Neoplasms, Hepatocellular carcinoma, Esophageal cancer, Intesti-
nal Diseases, Stomach Diseases, Stomach cancer, Gastric cancer, Liver Diseases, Liver Neoplasms, Pancreatic 
Diseases, Signaling Pathways, Signal Transduction, Wnt Signaling Pathway, and MAP Kinase Signaling System 
between January 1998 and September 28, 2019. Also, the reference lists of the screened studies were reviewed 
so as to find relevant studies (the exact search strategy is available in the supplement data of supplementary 
Table 1).
inclusion and exclusion criteria. The studies were screened by two independent authors and all the stud-
ies meeting the inclusion criteria were included. Any discrepancy between the two reviewer authors were sorted 
out by a third expert. Inclusion criteria were the English language writing, publication up to the date of the 
search, the study setting of cross-sectional or cohort, and the data eligibility for the study. Furthermore, the 
meta-analysis, conference seminars, and review articles were excluded from the search results.
Data extraction. Selected studies were listed in EndNote software (EndNote X7, Thomson Reuters) and 
were reviewed by two authors of the study independently; disagreements between them were settled by a third 
expert. All the relevant studies were screened considering the inclusion criteria and the data were extracted. The 
extracted data included the first author’s name, the publication date (based on year), country, design of the study, 
type of the cancer, sample size, mutation pathway, gene name, mean age, gender, mutation positive population, 
and method of detection.
Risk bias assessment. The risk bias for the non-randomized controlled trials (RCT) was assessed making 
use of the 13 items in the Research Triangle Institute (RTI), Evidence-based Practice  Center187.
Meta‑analysis. In this study, to compute of the pooled estimate of prevalence we used the Metaprop com-
mand and random models with confidence interval of CI = 95%. The prevalence estimation performed by ran-
dom effects models in some analyses due to statistically significant of the heterogeneity test. In the present study, 
for the evaluation of statistical heterogeneity between studies we used Cochran’s Q test and  I2 statistics. In addi-
tion, for the assessment of the source of heterogeneity among studies we used subgroup analysis. Also, funnel 
plot and Egger test used for the publication bias assessment. For the statistical analysis in this study STATA 16.0 
(Stata Corp, College Station, TX, USA) were used by setting the statistical significant value at p < 0.05.
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